Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Prime Medicine, Inc. (PRME : NSDQ)

• Company Description    Prime Medicine Inc. is a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies. Prime Medicine Inc. is based in CAMBRIDGE, Mass. Number of Employees: 146

• Price / Volume Information    Yesterday's Closing Price: $2.97 Daily Weekly Monthly 20 Day Moving Average: 2,338,079 shares Shares Outstanding: 180.62 (millions) Market Capitalization: $536.43 (millions) Beta: 2.35 52 Week High: $6.94 52 Week Low: $1.18 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -22.66% -26.43% 12 Week -32.19% -37.31% Year To Date -14.41% -21.84%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 60 First Street - Cambridge,MA 02141 USA ph: 617-465-0013 fax: - hannah.deresiewicz@sternir.com https://primemedicine.com

• General Corporate Information    Officers Allan Reine - Chief Executive Officer and Chief Financial Office Carman Alenson - Chief Accounting Officer Thomas Cahill - Director Wendy Chung - Director Kaye Foster - Director Peer Information Prime Medicine, Inc. (CORR.) Prime Medicine, Inc. (RSPI) Prime Medicine, Inc. (CGXP) Prime Medicine, Inc. (BGEN) Prime Medicine, Inc. (GTBP) Prime Medicine, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 74168J101 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/06/26 Share - Related Items Shares Outstanding: 180.62 Most Recent Split Date: (:1) Beta: 2.35 Market Capitalization: $536.43 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.24 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.98 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 8.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/06/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 6.99 Price/Cash Flow: - Price / Sales: 132.98 EPS Growth vs. Year Ago Period: 30.00% vs. Previous Quarter: -27.27% Sales Growth vs. Year Ago Period: -41.13% vs. Previous Quarter: 2.15% ROE 03/31/26 - -188.82 12/31/25 - -178.60 09/30/25 - -163.51 ROA 03/31/26 - -60.97 12/31/25 - -60.27 09/30/25 - -61.21 Current Ratio 03/31/26 - 3.80 12/31/25 - 4.84 09/30/25 - 6.61 Quick Ratio 03/31/26 - 3.80 12/31/25 - 4.84 09/30/25 - 6.61 Operating Margin 03/31/26 - -4,917.55 12/31/25 - -4,342.44 09/30/25 - -3,301.64 Net Margin 03/31/26 - -4,917.55 12/31/25 - -4,342.44 09/30/25 - -3,301.64 Pre-Tax Margin 03/31/26 - -4,917.55 12/31/25 - -4,342.44 09/30/25 - -3,301.64 Book Value 03/31/26 - 0.42 12/31/25 - 0.67 09/30/25 - 0.90 Inventory Turnover 03/31/26 - - 12/31/25 - - 09/30/25 - - Debt-to-Equity 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - 0.00 Debt-to-Capital 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - 0.00

Powered by Zacks Investment Research ©